Compare Cytokinetics Inc (CYTK) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs PAGSEG Inc — how do they compare? Cytokinetics Inc trades at $77.04 (market cap $10.63B), while PAGSEG Inc trades at $8.75 (market cap $2.48B). The key difference: Cytokinetics Inc is far larger — about 4.3× PAGSEG Inc's market cap, and PAGSEG Inc pays a 11.7% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | PAGS | |
|---|---|---|
Market Cap | $10.63B | $2.48B |
Sector | Technology | Technology |
52-Week High | $87.26 | $12.00 |
52-Week Low | $34.31 | $8.38 |
Enterprise Value | $10.74B | $10.22B |
Dividend Yield | — | 11.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
PAGS trades at $8.59, down 5.4% in the last session, with a bearish technical signal despite attractive valuation metrics (P/E 6.17, P/S 0.64). The company reported $20.41B revenue and $2.12B net income for 2025, maintaining stable profitability with a 10.4% net margin. Recent Q2 2026 earnings beat expectations with EPS of $0.41 versus $0.389 expected, while analyst consensus remains bullish with a $11.45 price target.
The stock presents a value opportunity given its discounted valuation and strong analyst support (62.5% buy ratings), but faces headwinds from technical weakness and competitive pressures in Brazil's digital banking sector. Upside potential exists if earnings momentum continues, though investors should monitor execution risks and macroeconomic conditions affecting Brazilian financial markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
